SanegeneBio raises $110m for RNAi, plus other financings

RNA interference drug developer SanegeneBio has secured $110 million in a Series B financing round, which saw participation from pharmaceutical giant Eli Lilly. The funding will be used to advance its pipeline of RNAi-based drug candidates for autoimmune and cardiometabolic diseases.